- Home
- RAYA vs CERO Comparison
RAYA vs CERO Comparison
Compare RAYA & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAYA
- CERO
- Stock Information
- Founded
- RAYA 2019
- CERO 2017
- Country
- RAYA China
- CERO United States
- Employees
- RAYA N/A
- CERO N/A
- Industry
- RAYA Metal Fabrications
- CERO
- Sector
- RAYA Consumer Discretionary
- CERO
- Exchange
- RAYA Nasdaq
- CERO Nasdaq
- Market Cap
- RAYA 6.1M
- CERO 5.6M
- IPO Year
- RAYA 2022
- CERO N/A
- Fundamental
- Price
- RAYA $0.04
- CERO $5.52
- Analyst Decision
- RAYA
- CERO Strong Buy
- Analyst Count
- RAYA 0
- CERO 2
- Target Price
- RAYA N/A
- CERO $45.00
- AVG Volume (30 Days)
- RAYA 60.9M
- CERO 302.9K
- Earning Date
- RAYA 01-01-0001
- CERO 08-22-2025
- Dividend Yield
- RAYA N/A
- CERO N/A
- EPS Growth
- RAYA N/A
- CERO N/A
- EPS
- RAYA N/A
- CERO N/A
- Revenue
- RAYA $30,300,360.00
- CERO N/A
- Revenue This Year
- RAYA $20.95
- CERO N/A
- Revenue Next Year
- RAYA N/A
- CERO N/A
- P/E Ratio
- RAYA N/A
- CERO N/A
- Revenue Growth
- RAYA 49.10
- CERO N/A
- 52 Week Low
- RAYA $0.03
- CERO $4.27
- 52 Week High
- RAYA $3.35
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- RAYA 27.91
- CERO 33.04
- Support Level
- RAYA $0.05
- CERO $4.27
- Resistance Level
- RAYA $0.05
- CERO $7.60
- Average True Range (ATR)
- RAYA 0.01
- CERO 0.53
- MACD
- RAYA 0.05
- CERO -0.21
- Stochastic Oscillator
- RAYA 20.00
- CERO 31.37
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.